| Source: HalifaxProj(inhibit) |
| Type: |
| Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes; Akt2 is an important signaling molecule in the insulin signaling pathway. It is required to induce glucose transport. Inhibitors: -Curcumin: downregulate AKT phosphorylation and signaling. -Resveratrol -Quercetin: inhibit the PI3K/AKT pathway. -Epigallocatechin Gallate (EGCG) -Luteolin and Apigenin: inhibit AKT phosphorylation |
| 1184- | DHA, | Syndecan-1-Dependent Suppression of PDK1/Akt/Bad Signaling by Docosahexaenoic Acid Induces Apoptosis in Prostate Cancer |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | NA, | NA |
| 1844- | dietFMD, | Unlocking the Potential: Caloric Restriction, Caloric Restriction Mimetics, and Their Impact on Cancer Prevention and Treatment |
| - | Review, | NA, | NA |
| 1854- | dietFMD, | How Far Are We from Prescribing Fasting as Anticancer Medicine? |
| - | Review, | Var, | NA |
| 1860- | dietFMD, | Chemo, | Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape |
| - | in-vitro, | BC, | SUM159 | - | in-vitro, | BC, | 4T1 |
| 2269- | dietMet, | Mechanisms of Increased In Vivo Insulin Sensitivity by Dietary Methionine Restriction in Mice |
| - | in-vivo, | Nor, | NA |
| 2263- | dietMet, | Methionine Restriction and Cancer Biology |
| - | Review, | Var, | NA |
| 4987- | Dipy, | ATV, | Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination |
| - | in-vivo, | Nor, | NA |
| 5012- | DSF, | Cu, | Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems |
| 1607- | EA, | Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions |
| - | Review, | GC, | NA |
| 1605- | EA, | Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence |
| - | Review, | Var, | NA |
| 1621- | EA, | The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art |
| - | Review, | Var, | NA |
| 1606- | EA, | Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells |
| - | in-vitro, | Colon, | HCT15 |
| 1608- | EA, | Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
| 1610- | EA, | Anticancer Effect of Pomegranate Peel Polyphenols against Cervical Cancer |
| - | Review, | Cerv, | NA |
| 1618- | EA, | A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action |
| - | Review, | BC, | NA |
| 27- | EA, | Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice |
| - | in-vivo, | PC, | PANC1 |
| 1036- | EGCG, | Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | LU99 |
| 20- | EGCG, | Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer |
| - | in-vivo, | Liver, | NA | - | in-vivo, | Tong, | NA |
| 692- | EGCG, | EGCG: The antioxidant powerhouse in lung cancer management and chemotherapy enhancement |
| - | Review, | NA, | NA |
| - | in-vitro, | PC, | NA |
| 684- | EGCG, | Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation |
| - | in-vitro, | CRC, | NA |
| 680- | EGCG, | Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea |
| - | Review, | NA, | NA |
| 3205- | EGCG, | The Role of Epigallocatechin-3-Gallate in Autophagy and Endoplasmic Reticulum Stress (ERS)-Induced Apoptosis of Human Diseas |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2459- | EGCG, | Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2‑mediated glycolysis |
| - | in-vitro, | Tong, | Tca8113 | - | in-vitro, | Tong, | TSCCa |
| 5225- | EMD, | Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3 |
| - | vitro+vivo, | HCC, | HepG2 | - | in-vitro, | HCC, | Hep3B | - | in-vitro, | HCC, | HUH7 |
| 5223- | EMD, | Emodin inhibits colon cancer by altering BCL-2 family proteins and cell survival pathways |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | Nor, | CCD841 |
| 988- | EMD, | Emodin Induced Necroptosis and Inhibited Glycolysis in the Renal Cancer Cells by Enhancing ROS |
| - | in-vitro, | RCC, | NA |
| 1327- | EMD, | Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway |
| - | in-vitro, | Lung, | A549 |
| 1322- | EMD, | The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers |
| - | Review, | Var, | NA |
| 1324- | EMD, | Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin |
| - | Review, | Var, | NA |
| 1325- | EMD, | PacT, | Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo |
| - | vitro+vivo, | Lung, | A549 |
| 1320- | EMD, | SRF, | Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism |
| - | vitro+vivo, | HCC, | HepG2 | - | in-vitro, | HCC, | Hep3B | - | in-vitro, | HCC, | HUH7 | - | vitro+vivo, | Hepat, | SK-HEP-1 |
| 1155- | F, | The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations |
| - | Review, | NA, | NA |
| 1654- | FA, | Molecular mechanism of ferulic acid and its derivatives in tumor progression |
| - | Review, | Var, | NA |
| 1656- | FA, | Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling |
| - | Review, | Var, | NA |
| 3782- | FA, | Ferulic acid ameliorates bisphenol A (BPA)-induced Alzheimer’s disease-like pathology through Akt-ERK crosstalk pathway in male rats |
| - | in-vivo, | AD, | NA |
| 3712- | FA, | Ferulic Acid: A Hope for Alzheimer’s Disease Therapy from Plants |
| - | Review, | AD, | NA |
| 2847- | FIS, | Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells |
| - | in-vitro, | CCA, | NA |
| 2849- | FIS, | Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells |
| - | in-vitro, | Melanoma, | U266 |
| 2857- | FIS, | A review on the chemotherapeutic potential of fisetin: In vitro evidences |
| - | Review, | Var, | NA |
| - | in-vitro, | OS, | U2OS |
| 2845- | FIS, | Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy |
| - | Review, | Var, | NA |
| 2824- | FIS, | Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics |
| - | Review, | Var, | NA |
| 2825- | FIS, | Exploring the molecular targets of dietary flavonoid fisetin in cancer |
| - | Review, | Var, | NA |
| 2826- | FIS, | Fisetin induces apoptosis in breast cancer MDA-MB-453 cells through degradation of HER2/neu and via the PI3K/Akt pathway |
| - | in-vitro, | BC, | MDA-MB-453 |
| 2828- | FIS, | Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review |
| - | Review, | Var, | NA |
| 2829- | FIS, | Fisetin: An anticancer perspective |
| - | Review, | Var, | NA |
| 2830- | FIS, | Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent |
| - | Review, | Var, | NA |
| 2839- | FIS, | Dietary flavonoid fisetin for cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2843- | FIS, | Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:4 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid